Novo Nordisk has announced that over the next two years, some of their older generations of insulin products, including those with multiple presentations, will be phased out. This is part of a global insulin portfolio consolidation and is not a result of any safety, efficacy, or quality-related concerns.
This process will take place over an extended period of time and there is no requirement for community members to speak with their healthcare providers (HCPs) about these changes urgently. HCPs are being informed about these changes and may discuss with them with you in routine appointments over the coming months or years, depending on which insulin you are prescribed.
The full list of changes in Australia, including the specific presentations being discontinued, can be seen at the table below. Please note these changes do not include the currently PBS-listed Fiasp® Penfill.
| Insulin | Presentation being discontinued | Approximate supply end date | Novo Nordisk® presentations remaining available |
| Mixtard® 30 | Penfill® (currently PBS listed) | October 2024 | None |
| Fiasp® | Vials (not PBS listed) | December 2024 | Penfill® (PBS listed) |
| Ryzodeg® | FlexTouch (PBS listed) | February 2025 | Penfill® (PBS listed) |
| Protaphane® | InnoLet® (PBS listed) | February 2025 | Penfill® and Vials (PBS listed) |
| Fiasp® | FlexTouch (not PBS listed) | March 2025 | Penfill® (PBS listed) |
| Protaphane® | Penfill® (PBS listed) | December 2026 | Vials (PBS listed) |
| Levemir® | FlexPen® & Penfill® (PBS listed) | December 2026 | None |
| Actrapid® | Penfill® (PBS listed) | December 2026 | Vials (PBS listed) |
| NovoFine® Autocover | NovoFine® Autocover | December 2026 | None |
We will continue to provide updates to the community on these changes as they become available.
For any questions about these changes or their timings, reach out to the Novo Nordisk Medical Information Team on [email protected] or 1800 668 626.
